Treatment outcomes of stereotactic body radiation therapy using a real‐time tumor‐tracking radiotherapy system for hepatocellular carcinomas

Autor: Norio Katoh, Hiroshi Taguchi, Daisuke Abo, Ryo Morita, Takeshi Soyama, Takuya Sho, Masato Nakai, Ryusuke Suzuki, Tatsuhiko Kakisaka, Tatsuya Orimo, Koji Ogawa, Hidefumi Aoyama, Toshiya Kamiyama, Kentaro Nishioka, Koichi Yasuda, Shinichi Shimizu, Naoki Miyamoto, Y. Uchinami
Rok vydání: 2021
Předmět:
Zdroj: Hepatology Research.
ISSN: 1872-034X
1386-6346
DOI: 10.1111/hepr.13649
Popis: AIM To report the outcomes of stereotactic body radiotherapy using a real-time tumor-tracking radiotherapy system for hepatocellular carcinoma patients. METHODS From January 2005 to July 2018, 63 patients with 74 lesions with a maximum diameter ≤52 mm were treated by stereotactic body radiotherapy using a real-time tumor-tracking radiotherapy system. No patient with a Child-Pugh Score ≥9 was included, and 85.6% had a score of 5 or 6. Using the biological effective dose (BED) with an α/β ratio of 10 (BED10 ), the median dose in BED10 at the reference point was 76.8 Gy (range 60-122.5 Gy). Overall survival (OS) and local control rates were assessed using the Kaplan-Meier method. RESULTS With a median follow-up period of 24.6 months (range 0.9-118.4 months), the 1-year and 2-year OS rates were 86.8% (95% confidence interval [95% CI] 75.8-93.3) and 71.1% (57.8-81.6), respectively. The 2-year OS was 89.6% in patients with the baseline modified albumin-bilirubin (mALBI) grade =1, and 61.7% in patients with grade ≥2a. In the multivariate analysis, the mALBI grade (=1 vs. ≥2a) was a significant factor for OS (p = 0.028, 95% CI 1.11-6.18). The 1-year and 2-year local control rates were 100% (100-100%) and 92.0% (77.5-97.5%). The local control rates were significantly higher in the BED10 ≥100 Gy group than in the BED10
Databáze: OpenAIRE
Externí odkaz: